409 related articles for article (PubMed ID: 27054610)
1. Early effect on general interest, and short-term antidepressant efficacy and safety of agomelatine (25-50mg/day) and escitalopram (10-20mg/day) in outpatients with Major Depressive Disorder. A 12-week randomised double-blind comparative study.
Udristoiu T; Dehelean P; Nuss P; Raba V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2016 Jul; 199():6-12. PubMed ID: 27054610
[TBL] [Abstract][Full Text] [Related]
2. Comparable efficacy and safety of 8 weeks treatment with agomelatine 25-50mg or fluoxetine 20-40mg in Asian out-patients with major depressive disorder.
Shu L; Sulaiman AH; Huang YS; Fones Soon Leng C; Crutel VS; Kim YS
Asian J Psychiatr; 2014 Apr; 8():26-32. PubMed ID: 24655622
[TBL] [Abstract][Full Text] [Related]
3. Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients.
Quera-Salva MA; Hajak G; Philip P; Montplaisir J; Keufer-Le Gall S; Laredo J; Guilleminault C
Int Clin Psychopharmacol; 2011 Sep; 26(5):252-62. PubMed ID: 21829106
[TBL] [Abstract][Full Text] [Related]
4. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study.
Hale A; Corral RM; Mencacci C; Ruiz JS; Severo CA; Gentil V
Int Clin Psychopharmacol; 2010 Nov; 25(6):305-14. PubMed ID: 20856123
[TBL] [Abstract][Full Text] [Related]
5. 12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder.
Stein DJ; Khoo JP; Ahokas A; Jarema M; Van Ameringen M; Vavrusova L; Hӧschl C; Bauer M; Bitter I; Mosolov SN; Olivier V; Matharan S; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2018 Aug; 28(8):970-979. PubMed ID: 30135032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial.
Yu YM; Gao KR; Yu H; Shen YF; Li HF
J Clin Psychopharmacol; 2018 Jun; 38(3):226-233. PubMed ID: 29620692
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline.
Kasper S; Hajak G; Wulff K; Hoogendijk WJ; Montejo AL; Smeraldi E; Rybakowski JK; Quera-Salva MA; Wirz-Justice AM; Picarel-Blanchot F; Baylé FJ
J Clin Psychiatry; 2010 Feb; 71(2):109-20. PubMed ID: 20193645
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of agomelatine and escitalopram on depression, subjective sleep and emotional experiences in patients with major depressive disorder: a 24-wk randomized, controlled, double-blind trial.
Corruble E; de Bodinat C; Belaïdi C; Goodwin GM;
Int J Neuropsychopharmacol; 2013 Nov; 16(10):2219-34. PubMed ID: 23823799
[TBL] [Abstract][Full Text] [Related]
10. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
11. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
12. A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline.
Demyttenaere K; Corruble E; Hale A; Quera-Salva MA; Picarel-Blanchot F; Kasper S
CNS Spectr; 2013 Jun; 18(3):163-70. PubMed ID: 23472671
[TBL] [Abstract][Full Text] [Related]
13. Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months.
Kennedy SH; Avedisova A; Belaïdi C; Picarel-Blanchot F; de Bodinat C
Eur Neuropsychopharmacol; 2016 Feb; 26(2):378-389. PubMed ID: 26708320
[TBL] [Abstract][Full Text] [Related]
14. Effect of agomelatine 25-50 mg on functional outcomes in patients with major depressive disorder.
Kennedy SH; Heun R; Avedisova A; Ahokas A; Olivier V; Picarel-Blanchot F; de Bodinat C
J Affect Disord; 2018 Oct; 238():122-128. PubMed ID: 29879606
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of agomelatine in the treatment of major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled trial.
Zajecka J; Schatzberg A; Stahl S; Shah A; Caputo A; Post A
J Clin Psychopharmacol; 2010 Apr; 30(2):135-44. PubMed ID: 20520286
[TBL] [Abstract][Full Text] [Related]
16. Agomelatine in the treatment of major depressive disorder: an 8-week, multicenter, randomized, placebo-controlled trial.
Stahl SM; Fava M; Trivedi MH; Caputo A; Shah A; Post A
J Clin Psychiatry; 2010 May; 71(5):616-26. PubMed ID: 20361916
[TBL] [Abstract][Full Text] [Related]
17. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
18. Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France.
Gorwood P; Benichou J; Moore N; Wattez M; Secouard MC; Desobry X; Picarel-Blanchot F; de Bodinat C
Clin Drug Investig; 2020 Nov; 40(11):1009-1020. PubMed ID: 32729068
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of agomelatine on anhedonia in depressed patients: an outpatient, open-label, real-world study.
Gargoloff PD; Corral R; Herbst L; Marquez M; Martinotti G; Gargoloff PR
Hum Psychopharmacol; 2016 Nov; 31(6):412-418. PubMed ID: 27859669
[TBL] [Abstract][Full Text] [Related]
20. Novel Augmentation Strategies in Major Depression.
Martiny K
Dan Med J; 2017 Apr; 64(4):. PubMed ID: 28385173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
